NJ Doctor Excluded from Medicare, Forfeits DEA License Quietly
Published Date: 9/29/2026
Notice
Summary
Dr. Jorge J. Figueroa from New Jersey lost his DEA registration because he was kicked out of Medicare, Medicaid, and other federal health programs. He didn’t ask for a hearing, so the DEA made the decision official. This means he can’t legally handle controlled substances anymore, effective immediately, impacting his medical practice and income.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA registration revoked (FF1775660)
The Drug Enforcement Administration revoked DEA Certificate of Registration No. FF1775660 issued to Jorge J. Figueroa, M.D. The Order of revocation is effective October 29, 2026, ending his DEA registration under the Controlled Substances Act.
Pending registration applications denied
The Order denies any pending applications by Jorge J. Figueroa, M.D., to renew or modify Certificate No. FF1775660 and denies any other pending application for additional registration in New Jersey. The denial was issued as part of the final Order effective October 29, 2026.
Mandatory exclusion from federal health programs
HHS/OIG mandatorily excluded Jorge J. Figueroa, M.D., from participation in Medicare, Medicaid, and all Federal health care programs effective April 19, 2018, for a minimum period of 15 years pursuant to 42 U.S.C. 1320a-7(a). The DEA relied on that mandatory exclusion as the basis for revoking his registration under 21 U.S.C. 824(a)(5).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2026-19837, Proposed Extension of Information Collection: Certification and Qualification To Examine, Test, Operate Hoists and Perform Other Duties
The Mine Safety and Health Administration wants to keep collecting info on certifying and qualifying people who operate hoists and do related tasks in mines. This helps keep miners safe by making sure only qualified folks handle this important equipment. They’re asking for public comments by November 30, 2026, and there’s no new cost or big changes—just a smooth extension of the current process.
Next: 2026-19840, Christopher Nadorff, M.D.; Decision and Order
Dr. Christopher Nadorff from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.